Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
Status:
Active, not recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This is a randomized, sham controlled, masked clinical trial of 60 study participants with
glaucoma. Participants with a qualifying study eye will be randomized after screening and
baseline evaluations to receive the NT-501 encapsulated cell therapy (ECT) implant or a sham
surgery (control arm), and no explant will be required.
An examination for safety will occur one day and one week following implant and periodically
thereafter for 24 months post-implant. Based on the primary analysis of data at 6 months,
patients in the control arm may be offered the NT-501 ECT implant at the 12 month time point.